B
Bullisch
Bullisch · 25%KYTX
$4.24
Szenariopreis
$5.390
-0.320 (-5.93%)Zum Schluss
Loading chart…
- Hoch
- 5.730
- Eröffnung
- 5.650
- Volumengewichteter Durchschnittskurs
- 5.49
- Volumen
- 827.03K
- Marktkap.
- —
- Tief
- 5.360
- Umsatz
- 4.54M
- EV/EBITDA, TTM
- 0.00
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
KI-Analyse of Kyverna Therapeutics Inc (KYTX)
VerkaufenKyverna Therapeutics Inc is not a good buy right now due to its current price of $5.67, which is significantly below the analyst price targets of $25 and $29. However, the stock has seen a 35.35% decline year-to-date, indicating potential for recovery. The RSI is at 29.778, suggesting the stock is oversold, but the negative earnings trend with a forward P/E of 0 and consistent losses (latest EPS reported at -0.63) raises concerns about its financial health. The main risk is the ongoing net losses, with a net income of -39,728,000 USD in Q1 2026, which could hinder future growth and recovery.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Kyverna Therapeutics Inc (KYTX) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -2.51.
Alphio-AI-Kursszenarien für KYTX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die KYTX halten
Event-Zeitleiste
News
9.010-23NewsfilterMiv-cel Shows Promising Efficacy in Progressive Multiple Sclerosis
7.010-22PRnewswireInvestigation into Kyverna Therapeutics' Corporate Governance Breaches
- 7.010-22Newsfilter
Investigation into Kyverna Therapeutics' Fiduciary Duties
- 9.010-21Newsfilter
Miv-cel Achieves Breakthrough Efficacy in Stiff Person Syndrome
9.009-24stocktwitsKyverna's Miv-cel Shows Promising Results in Stiff Person Syndrome Study
KYTX FAQ – beantwortet von Alphio AI
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Kyverna Therapeutics Inc is not a good buy right now due to its current price of $5.67, which is significantly below the analyst price targets of $25 and $29. However, the stock has seen a 35.35% decline year-to-date, indicating potential for recovery. The RSI is at 29.778, suggesting the stock is oversold, but the negative earnings trend with a forward P/E of 0 and consistent losses (latest EPS reported at -0.63) raises concerns about its financial health. The main risk is the ongoing net losses, with a net income of -39,728,000 USD in Q1 2026, which could hinder future growth and recovery.
Community
Mehr ↗
$KYTX Swarmer's miv-cel shows positive results in stiff person syndrome and gMG Kyverna Therapeutics announced positive one-year topline data from KYSA-8, its registrational trial of miv-cel - mivocabtagene autoleucel, KYV-101 - in patients with stiff person syndrome or SPS, and positive topline longer-term follow-up data from the Phase 2 portion of KYSA-6, its registrational trial in patients with generalized myasthenia gravis, or gMG. Data from both trials will be shared at upcoming medical meetings. The primary endpoint and all key secondary endpoints were achieved with statistical significance in KYSA-8. The topline one-year durability data further strengthen the positive results. Miv-cel continued to be well-tolerated. Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE. Kyverna intends to include the one-year data in its rolling BLA submission, on track to be completed in Q4. The full data set will be presented at MS Toronto, October 21-23, in Toronto. All 7 patients achieved clinically meaningful improvement in MG-ADL and QMG, co-primary endpoints of the ongoing Phase 3 portion. All 7 patients remained free of immunotherapies for MG. Miv-cel continued to be well-tolerated. The Phase 3 portion of the KYSA-6 trial is ongoing, with enrollment expected to be completed in mid-2027.
Mehr anzeigenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.